Novel Sulfated Polysaccharides Disrupt Cathelicidins, Inhibit RAGE and Reduce Cutaneous Inflammation in a Mouse Model of Rosacea by Zhang, Jianxing et al.
Novel Sulfated Polysaccharides Disrupt Cathelicidins,
Inhibit RAGE and Reduce Cutaneous Inflammation in a
Mouse Model of Rosacea
Jianxing Zhang
1,2, Xiaoyu Xu
1,2, Narayanam V. Rao
3, Brian Argyle
1, Lindsi McCoard
1, William J. Rusho
4,
Thomas P. Kennedy
3*, Glenn D. Prestwich
1,2, Gerald Krueger
5
1Center for Therapeutic Biomaterials, University of Utah, Salt Lake City, Utah, United States of America, 2Department of Medicinal Chemistry, University of Utah, Salt Lake
City, Utah, United States of America, 3Department of Internal Medicine, University of Utah, Salt Lake City, Utah, United States of America, 4Department of Pharmaceutics
and Pharmaceutical Chemistry, University of Utah, Salt Lake City, Utah, United States of America, 5Department of Dermatology, University of Utah, Salt Lake City, Utah,
United States of America
Abstract
Background: Rosacea is a common disfiguring skin disease of primarily Caucasians characterized by central erythema of the
face, with telangiectatic blood vessels, papules and pustules, and can produce skin thickening, especially on the nose of
men, creating rhinophyma. Rosacea can also produce dry, itchy eyes with irritation of the lids, keratitis and corneal scarring.
The cause of rosacea has been proposed as over-production of the cationic cathelicidin peptide LL-37.
Methodology/Principal Findings: We tested a new class of non-anticoagulant sulfated anionic polysaccharides, semi-
synthetic glycosaminoglycan ethers (SAGEs) on key elements of the pathogenic pathway leading to rosacea. SAGEs were
anti-inflammatory at ng/ml, including inhibition of polymorphonuclear leukocyte (PMN) proteases, P-selectin, and
interaction of the receptor for advanced glycation end-products (RAGE) with four representative ligands. SAGEs bound LL-
37 and inhibited interleukin-8 production induced by LL-37 in cultured human keratinocytes. When mixed with LL-37 before
injection, SAGEs prevented the erythema and PMN infiltration produced by direct intradermal injection of LL-37 into mouse
skin. Topical application of a 1% (w/w) SAGE emollient to overlying injected skin also reduced erythema and PMN infiltration
from intradermal LL-37.
Conclusions: Anionic polysaccharides, exemplified by SAGEs, offer potential as novel mechanism-based therapies for
rosacea and by extension other LL-37-mediated and RAGE-ligand driven skin diseases.
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Introduction
Rosacea is a common skin disease afflicting primarily Caucasian
women of Celtic descent [1]. Rosacea is characterized by central
erythema of the face, with telangiectatic blood vessels, papules and
pustules, and can produce skin thickening, especially on the nose
of men, creating rhinophyma. Rosacea can also produce dry, itchy
eyes with irritation of the lids, keratitis and corneal scarring. The
disease disfigures in a prominent manner, and its treatment is
empiric and imperfect [2]. The pathogenesis of rosacea has been
attributed in part to cutaneous over-production of a cationic anti-
microbial cathelicidin peptide produced by the processing serine
proteinase stratum corneum tryptic enzyme (SCTE) [3,4].
Cathelicidins are highly cationic 18 kDa propeptides cleaved to
an active 37-amino acid C-terminal anti-microbial peptide, LL-37
[5]. LL-37 induces interleukin-8 (IL-8) secretion by human
keratinocytes, and injection of LL-37 into mouse skin recapitulates
rosacea-like redness and PMN infiltration [3].
We have evaluated a family of sulfated and metabolically
stabilized anionic polysaccharide derivatives known as semi-
synthetic glycosaminoglycan ethers (SAGEs). We hypothesized
that a topically-applied SAGE could be used as a novel therapy for
rosacea by binding and inhibiting the inflammatory activity of
excess cationic cathelicidins. We show that one SAGE, GM-1111,
exhibits substantial anti-inflammatory activities at nanomolar
concentrations, including inhibition of cationic PMN proteases,
inhibition of the leukocyte adhesion receptor P-selectin, and
inhibition of the interaction of the receptor for advanced glycation
end-products (RAGE) with its disparate ligands. GM-1111 avidly
bound LL-37 and inhibited IL-8 secretion in cultured human
keratinocytes in response to LL-37 stimulation. When mixed with
LL-37, SAGEs prevented the extensive erythema and PMN
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mouse skin [3]. More importantly, topical application of a 1%
SAGE-containing emollient to overlying injected skin also
substantially reduced the redness and cutaneous PMN infiltration
induced by intradermal LL-37. Herein, data demonstrate anionic
polysaccharides, exemplified by SAGEs, as the first mechanism-
based therapy that targets the proposed molecular etiology of
rosacea.
Results
SAGEs are non-animal derived
Twenty-five novel derivatives of hyaluronic acid (HA) were
obtained from GlycoMira, LLC (Salt Lake City, UT). HA is an
immunoneutral skin polysaccharide consisting of long polymers
(up to 10 MDa) of the disaccharide N-acetylglucosamine (GlcNAc)
and glucuronic acid (GlcA) linked GlcNacb1-3GlcAb1-4 in
repeating units along the chain. Fermentation-derived HA was
chemically alkylated to provide lipophilicity to both improve
dermal penetration and reduce hydrolysis by hyaluronidases [6].
Subsequently, the HA ethers were sulfated to adjust polyanionic
charge and anti-inflammatory properties. The HA used as a
starting material varied from 50 kDa to 950 kDa. A representative
SAGE structure is illustrated in Figure 1. For further study, we
chose the SAGE GM-1111, which was produced from 53 kDa HA
and had a final molecular weight of 5.5 kDa.
SAGEs bind P-selectin, Mac-1 and RAGE, and potently
inhibit P-selectin, cationic PMN proteases and interaction
of RAGE with its disparate ligands
The SAGE GM-1111 showed anti-inflammatory activities
similar to those of heparin or its low anticoagulant analogs [6]
in a number of in vitro assays.
First, SAGEs avidly bound to the adhesion molecule P-selectin,
the Mac-1 integrin (CD11b/CD18) and the multi-ligand immu-
noglobulin superfamily receptor RAGE. Figure 2 shows that GM-
1111 exhibited saturable binding to P-selectin with a KD of
0.0036 nM (Figure 2A), to Mac-1 with a KD of 0.175 nM
(Figure 2B) and to RAGE with a KD of 1.69 nM (Figure 2C).
Second, SAGEs were potent inhibitors of the leukocyte
adhesion molecule P-selectin [7]. Competitor-mediated displace-
ment of U937 human monocytes, which loosely adhere to P-
selectin through P-selectin glycoprotein ligand-1 (PSGL-1), was
studied using fluorescent-labeled U937 cells. Table 1 and
Figure 3A show that the SAGE GM-1111 inhibited U937 binding
to P-selectin with a 50% inhibitory concentration (IC50)o f
24.9 nM, approximately three times higher than the IC50 for
heparin (7.9 nM).
Third, as sulfated polyanions, SAGEs were potent inhibitors of
cationic PMN proteases such as human leukocyte elastase [8].
GM-1111 inhibited the PMN protease human leukocyte elastase
(HLE) with an IC50 of 44.7 nM (Table 1 and Figure 3B),
approximately three times higher than the IC50 of 14.9 nM for
heparin. Thus, the polyanionic nature of the SAGEs would be
expected to reduce protease activity in part via electrostatic
interactions. However, this simplistic explanation cannot account
for the totality of observed SAGE pharmacology in vitro [6].
Fourth, SAGEs were found to be potent inhibitors of RAGE
binding with its ligands. The advanced glycation end-product
(AGE) carboxymethyl lysine-modified (CML) protein is promi-
nently formed in the dermis as the consequence of sun exposure,
and avidly ligates and activates RAGE inflammatory signaling [9].
RAGE binds to immobilized CML-bovine serum albumin (BSA)
in a dose dependent manner with an equilibrium constant (KD)o f
0.43 nM [10]. GM-1111 potently inhibited interaction of CML-
BSA with RAGE (Table 1 and Figure 3C) with an with an IC50 of
413 nM. Once PMNs have migrated into inflamed dermis, PMN
secretion of S100 calgranulins provides an active RAGE ligand to
perpetuate inflammatory signaling even in the absence of AGE
products [11]. RAGE engages immobilized S100b in a dose-
dependent manner with a KD of 0.45 nM [10]. GM-1111
inhibited ligation of RAGE by S100b calgranulin with an IC50
of 275 nM, compared with IC50 of 92 nM for heparin (Table 1
and Figure 3D) Likewise, RAGE binds immobilized human high
mobility box group protein-1 (HMGB-1) in a saturable fashion
with a KD of 0.64 nM [10]. HMGB-1 is secreted by monocytes
and macrophages as an inflammation producing cytokine and is
also released by necrotic cells into areas of injury [12]. GM-1111
inhibited ligation of RAGE by HMGB-1 with an IC50 of 80 nM,
compared with an IC50 of 2.9 nM for heparin (Table 1 and
Figure 3E). Finally, using the Mac-1 (CD11b/CD18) as a counter-
ligand, leukocytes ligate RAGE on vascular endothelium as an
adhesion molecule essential for exiting the circulation into areas of
inflammation [13]. GM-1111 inhibited binding of U937 mono-
cytes to RAGE with an IC50 of 7.6 nM, essentially equipotent with
the IC50 of 7.9 nM for heparin (Table 1 and Figure 3F). Taken
together, these results suggest that SAGEs may provide consider-
able anti-inflammatory activity in diseases mediated by RAGE-
ligand interactions, including the skin, where RAGE likely plays a
role in lymphocyte-mediated diseases such as atopic dermatitis and
psoriasis, as well as photo-ageing.
SAGEs are safe when administered topically
When applied to cultured human dermal fibroblasts (nHDF)
and keratinocytes (nHEK), GM-1111 did not inhibit proliferation
or cause cell toxicity up to 1 mg/ml (data not shown).
Furthermore, none of the SAGEs tested, including GM-1111,
elicited any skin reaction in Draize tests up to 10 mg/ml [14] (data
not shown). SAGEs are also effectively non-anticoagulant in
nature; for example, GM-1111 has approximately 0.2–0.5% of the
anticoagulant activity of heparin. Specifically GM-1111 shows
values of 0.3 IU/mg anti-Xa activity and 0.8 IU/mg anti-IIa
activity, compared to 150–160 IU/mg each for unfractionated
heparin. Unlike heparin, many highly charged polyanionic
polymers are potent activators of Factor XII (Hagemann factor),
secondarily producing kinins [15]. GM-1111 failed to show any
activation of Factor XII [16], even at concentrations 10 to 100-
fold higher than needed to achieve pharmacologic inhibition of
Figure 1. Structure of semi-synthetic glycosaminoglycan ethers
(SAGEs). SAGEs can vary in molecular size, and in extent of alkylation
and sulfation. GM-1111 is a low-molecular weight SAGE with an average
molecular weight of 5.5 kDa.
doi:10.1371/journal.pone.0016658.g001
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that the GM-1111 was safe as a lead candidate for topical use.
SAGEs bind to LL-37 and inhibit the biologic activity of
LL-37 in vitro
The SAGE GM-1111 bound to the polycationic LL-37 peptide
in a saturable fashion with a KD of 0.225 nM (Figure 4A). This
suggests that at least some of the biologic activity of the
polyanionic SAGEs could be due to saturable, charge-neutraliza-
tion of the cationic cathelicidins. However, electrostatic interac-
tions alone cannot account for the overall SAGE pharmacology.
For example, similar to previous reports [3], LL-37 induced IL-8
secretion by cultured human keratinocytes (Figure 4B). Addition of
GM-1111 to the medium in addition to LL-37 significantly
reduced IL-8 production by cultured keratinocytes (Figure 4B).
SAGEs inhibit cutaneous inflammation from intradermal
LL-37
Intradermal injection of LL-37 into Balb/c mice at four 12-h
intervals for 48 h produced cutaneous erythema with central
necrosis (Figure 5A), prominent intradermal PMN infiltration
(Figure 5C and Figure 6B), marked edema of the dermis
(Figure 5C) and increased tissue myeloperoxidase (MPO) activity
(Figure 5E). This reproduced the previously described murine
model of rosacea [3]. The area of erythema (Figures 5B and F) and
redness score (3.860.5 after LL-37 alone vs 1.260.5 after LL-37+
SAGE, P,0.05) were both significantly reduced by co-injection of
GM-1111 with LL-37. Simultaneous injection of GM-1111 with
LL-37 also significantly decreased PMN infiltration, as assessed by
histology (Figure 5D) or tissue MPO activity (Figure 5E). Thus, at
a minimum, charge neutralization of LL-37 by SAGE co-injection
results in a significant reduction of LL-37-induced inflammation.
To determine if topical SAGEs were effective topical anti-
inflammatory agents in this rosacea model, we formulated GM-
1111 into a standard triglyceride-based transdermal emollient that
contained 20% (w/w) water and 1% (w/w) of active drug. LL-37
was injected intradermally every 12 h for 48 h. In treated animals
(n=6 per group), the injected skin was gently rubbed with
Figure 2. SAGEs bind to vascular adhesion proteins. GM-1111
was studied to determine binding affinity for P-selectin (A), Mac-1 (B),
and RAGE (C). Binding affinity (KD) values were 0.0036 nM for GM-1111
binding to P-selectin, 0.175 nM for GM-1111 binding to Mac-1 and
1.69 nM for GM-1111 binding to RAGE.
doi:10.1371/journal.pone.0016658.g002
Table 1. Anti-Inflammatory Activities of SAGE, GM-1111, In
Vitro
1.
Anti-Inflammatory Assay IC50 values (nM)
SAGE* Heparin*
1U937 monocyte binding to P-selectin 24.9 7.9
2Human Leukocyte Elastase activity 44.7 14.9
3CML-BSA binding to RAGE 412.7 27.8
3S100b binding to RAGE 274.5 92.1
3HMGB-1 binding to RAGE 79.6 2.9
1U937 monocyte binding to RAGE 7.6 7.9
*The average molecular mass of SAGE is 5.5 kDa and heparin is 14 kDa.
Details of
1cell surface binding assays,
2 inhibition of human leukocyte elastase
(HLE) and
3solid phase binding assays are found in Methods. Detailed graphical
plots of the results from cell surface binding assays, inhibition of HLE and solid
phase binding assays are shown in Figure 3.
doi:10.1371/journal.pone.0016658.t001
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6 standard deviation of quadruplicate wells for each concentration of SAGE. A. SAGEs inhibit P-selectin. Inhibition of P-selectin glycoprotein ligand-1
(PSGL-1) binding to P-selectin by SAGEs was studied using calcein-labeled U937 cells incubated in microwells coated with P-selectin. After 1 h, plates
were washed, bound cells were lysed with Triton-X100 buffer and bound cells were quantified using an excitation of 494 nm and emission of 517 nm.
GM-1111 inhibits PSGL-1 attachment to P-selectin with an IC50 of 25 nM. B. SAGEs inhibit HLE. HLE (100 nM) was incubated with GM-1111 at 1–
100 nm concentrations in 0.5 M HEPES buffer for 15 min. Following incubation, the elastase substrate, Suc-Ala-Ala-Val-pNA was added to the reaction
mixture to the final concentration of 0.3 mM. Absorbance due to p-NA hydrolysis was monitored for 15 min at absorbance of 405 nm. GM-1111
inhibits HLE with an IC50 of 45 nM. C–E. SAGEs inhibit interaction of the AGE product CML-BSA, the calgranulin S100b and the alarmin HMGB-1 with
RAGE. Microwell plates coated with CML-BSA (C), S100b calgranulin (D) or HMGB-1 (E) were incubated with RAGE-Fc chimera with or without GM-
1111 for 2 h. Plates were washed, incubated with anti-RAGE antibody, incubated for 1 h, washed again four times and incubated with horse-radish
peroxidase conjugated secondary for 1 h. A colorimetric reaction was produced by addition of tetramethyl benzidine chromogen (TMB) and
quantified by absorbance at 450 nm. GM-1111 inhibits interaction of RAGE with CM-BSA, S100b and HMGB-1 with IC50 values of 413, 275 and 80 nM,
respectively. F. SAGEs inhibit function of RAGE as an adhesion ligand. Inhibition of Mac-1-dependent ligation of RAGE by U937 cells was studied as in
A, but using microwells coated with RAGE. GM-1111 inhibits Mac-1 attachment to RAGE with an IC50 of 7.6 nM.
doi:10.1371/journal.pone.0016658.g003
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immediately (t=0) or 12 h after the first injection (t=12 h).
Emollient application was repeated after each of the intradermal
LL-37 injections. Cutaneous inflammation from intradermal LL-
37 was significantly reduced by topical 1% GM-1111 (Figure 7).
Whether applied at t=0 or t=12 h after the first LL-37 injection,
topical GM-1111-containing emollient significantly reduced both
erythema (t=0, Figure 7B; t=12 h, Figure 7C) and PMN
infiltration (t=0, Figures 7E, 7G and Figure 6C; t=12 h,
Figures 7F, 7G and Figure 6D) relative to untreated or vehicle
only animals receiving the intradermal LL-37. The SAGE-
containing emollient also significantly reduced the area of
erythema (Figure 7H) and redness score [4.660.3 after LL-37
alone, 1.660.4 after LL-37+ SAGE (t=0) and 1.560.5 after LL-
Figure 4. SAGE binds LL-37 and inhibits LL-37-induced interleukin-8 (IL-8) expression in vitro. A. SAGE binds LL-37. Microwell plates
coated with GM-111 were incubated with LL-37 at 37uC for 2 h. Plates were washed, incubated with anti-LL-37 antibody, incubated for 1 h, washed
again four times and incubated with peroxidase-conjugated secondary antibody for 1 h. A colorimetric reaction was produced by addition of TMB
and quantified by absorbance at 450 nm. LL-37 binds to GM-1111 with a KD of 0.225 nM. B. SAGE inhibits IL-8 production LL-37 stimulated
keratinocytes. Human keratinocytes were grown to confluence and treated with 3.2 mM LL-37 or LL-37 and a 4x molar excess of GM-111101 for 6 h.
Supernatants were collected and placed in a sterile 96-well plate. Production of IL-8 was determined by ELISA (R&D Systems, Minneapolis, MN) in
accordance with manufacturer’s instructions. Co-addition of GM-1111 significantly inhibited IL-8 release into medium. *P,0.01 as compared with
negative control group without LL37; **P,0.05 as compared with positive control group without GM-111101 treatment.
doi:10.1371/journal.pone.0016658.g004
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decreased MPO activity within biopsies of injected skin
(Figure 7G). Anti-inflammatory effects were not evident using
1% concentration of 53 kDa HA in the emollient in place of the
GM-1111 (Figure 8). Confocal microscopy was performed on LL-
37 injected mouse skin after topical treatment with emollient
containing fluorescent-labeled GM-1111 (Figure 9). In the
presence of irritant disruption of the stratum corneum, labeled
SAGE penetrated deeply into inflamed skin. These results support
our hypothesis that the SAGE GM-1111, but not HA, would be
topically effective in a pharmaceutically acceptable emollient to
treat the cathelicidin peptide-mediated elements of inflammation
associated with rosacea.
S100 calgranulins have not been previously reported as
pathobiologically important in rosacea, but their presence would
not be surprising in light of the prominent PMN infiltration in this
disease [1]. Immunohistochemical staining for the RAGE ligand
S100A8 confirmed the presence of this mouse homologue for the
Figure 5. SAGE co-injection inhibits erythema and PMN infiltration from intradermal LL-37. Balb/c mice were shaved to expose an area
of skin on the back. Twenty-four hours later, mice were intradermally injected with 40 ml of vehicle (nanopure water), LL-37 (at 320 mM concentration
in water), SAGE GM-1111 (1,280 mM in water), or LL-37+ GM-1111 mix (peptide +4 molar equivalents of SAGE) placed intradermally into the shaved
skin using a 31-gauge needle and 0.5 ml insulin syringe. Injections were repeated every 12 h thereafter. Forty-eight hours after the initial injection
(four injections in total), animals were lightly anesthetized with isoflurane, the area of injected skin was photographed, the intensity of erythema was
assessed as a redness score (from 1 to 5, with 5 as the most red), and the area of erythema was measured with micrometer calipers. The injected skin
was then biopsied for histopathologic staining and to assess PMN infiltration through measurement of myeloperoxidase (MPO) activity. A. Gross
picture of LL-37 injected skin region. B. Co-injection model of LL-37 and SAGE GM-1111. C. H&E-stained cross-sectional view of a LL-37 injected skin
sample. D. H&E-stained cross-sectional view of a LL-37 mixed with GM-1111- injected skin region. E. MPO activity measurement of LL-37 injection
with different treatments. F. Area of erythema from LL-37 injection. *P,0.05 vs intradermal LL-37 alone; n=6 per group.
doi:10.1371/journal.pone.0016658.g005
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injected skin (Figures 6E vs 6F). Importantly, topical GM-1111
treatment reduced S100A8 staining expression compared to LL-37
alone (Figures 6G and 6H vs 6F).
SAGEs inhibit cutaneous inflammation from croton oil
As another model, we employed croton oil, which is commonly
used to study PMN-mediated skin inflammation in screening anti-
inflammatory compounds for dermatologic use [18]. Croton oil
contains the phorbol ester tetradecyl phorbol acetate (TPA), which
activates protein kinase C in skin cells, producing abundant
chemotaxins which can signal PMN influx. Cutaneous inflamma-
tion from croton oil has also recently been linked in part to
recruitment of inflammatory cells by HMGB-1 released from
TPA-exposed keratinocytes [19]. When painted on the ear, croton
oil produces intense redness (Figure 10A bottom), accompanied by
edema (Figure 10C) and intradermal increase in MPO activity
(Figure 10E), indicative of PMN infiltration, compared to the
control ear (Figures 10A top, B and E). Topical application of
GM-1111 significantly decreased phorbol-induced ear edema
(Figure 10D), MPO activity (Figure 10E), increase in erythema
(Figure 10F), and increase in ear thickness (Figure 10G). This
indicates that topical SAGEs may have utility in treating other
dermatoses that are in part or completely mediated by PMNs.
Discussion
Herein we show that novel sulfated glycosaminoglycan ethers
have broad anti-inflammatory activity. The SAGE GM-1111
avidly bound to the leukocyte adhesion molecule P-selectin, the
Mac-1 integrin and the pro-inflammatory pattern recognition
receptor RAGE. This SAGE also potently inhibited P-selectin,
blocked catalytic activity of the cationic PMN protease HLE, and
inhibited the interaction of RAGE with its disparate ligands,
including the AGE product CML-BSA, the S100 calgranulin
S100b and the nuclear alarmin HMGB-1. Furthermore, GM-
1111 demonstrated the ability to block leukocytes from using
RAGE as an alternative adhesion ligand. The activities exempli-
fied by GM-1111 (Table 1 and Figures 2 and 3) are generally
demonstrated by a wide range of SAGEs with distinct structures
and distinctive structure-activity profiles [6]. In aggregate, these
activities would be predicted to be broadly anti-inflammatory. We
confirmed this to be the case using a recently reported model of
human rosacea [3]. LL-37 avidly bound to SAGE (Figure 4A) and
addition of GM-1111 to medium blocked the ability of LL-37 to
induce IL-8 expression by cultured human keratinocytes
(Figure 4B). Further, co-injection of GM-1111 with LL-37
inhibited development of erythema (Figures 5A vs B and F) and
skin infiltration of PMNs (Figure 5C vs 5D and 5E) in response to
intradermal LL-37 peptide. Topical GM-1111 was also effective at
Figure 6. Topical SAGE reduces PMN infiltration and S100 calgranulin accumulation from intradermal LL-37. LL-37, PBS and LL-37 and
SAGE-injected mouse skin was stained with antibody to mouse Gr-1 to examine neutrophil infiltration, and also for S100A8 calgranulin, the major
RAGE-binding calgranulin present in murine PMNs [17] as described in Methods. A. Staining of normal control skin for the PMN antigen Gr-1.
B. Staining of LL-37 injected skin for the PMN antigen Gr-1. C. Staining of skin injected with LL-37 plus GM-1111 (applied at t=0) for the PMN antigen
Gr-1. D. Staining of skin injected with LL-37 plus GM-1111 (applied at t=12 h) for the PMN antigen Gr-1. E. Staining of normal control skin for the
RAGE ligand S100A8. F. Staining of LL-37 injected skin for the RAGE ligand S100A8. G. Staining of skin injected with LL-37 plus GM-1111 (applied at
t=0) for the RAGE ligand S100A8. H. Staining of skin injected with LL-37 plus GM-1111 (applied at t=12 h) for the RAGE ligand S100A8. Figures and
insets are shown at 20x and 40x magnification, respectively.
doi:10.1371/journal.pone.0016658.g006
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similarly reduced inflammatory edema and PMN infiltration in
response to dermal application of croton oil (Figure 10). Thus,
topical SAGEs are the first mechanistically based approach for
treating rosacea that intersects with currently understood patho-
genic mechanisms in this disease [3], and may also be therapeutic
for other leukocyte mediated skin disorders.
Cathelicidin peptides are polycationic antimicrobial peptides
important for innate immunity of skin and other organs [5]. In
humans, the major cathelicidin peptide is LL-37, which is
produced by proteolytic processing of its precursor hCAP18
(human cationic antimicrobial protein 18). In addition to being
antimicrobial, antifungal and antiviral, LL-37 is chemoattractant
through activation of the formyl peptide receptor-like 1 (FPRL1)
receptor on leukocytes, and can induce keratinocyte IL-8 and IL-
18 secretion through activation of the epidermal growth factor
receptor or the p38 and ERK1/2 MAP kinase pathways,
respectively [5]. Through FPRL1, LL-37 also activates endothelial
cells, resulting in angiogenesis [20]. These activities account for the
erythema, telangiectases and PMN infiltration of rosacea [3].
The polyanionic glycosaminoglycan heparin has been previ-
ously reported to inhibit LL-37 binding to lipopolysaccharide [21]
Figure 8. HA emollient does not reduce LL-37-induced inflammation. Experiments were performed as in Figure 7, but with immediate (t=0)
application of 1% w/w HA-containing emollient (53 kDa HA) or 1% w/w GM-1111 emollient. *P,0.05 vs LL-37 alone. A. H&E-stained cross-sectional
view of LL-37 injected skin. B. H&E-stained section of LL-37 injected skin treated with topical HA emollient alone. C. H&E-stained section of LL-37
injected skin treated with topical emollient containing 1% SAGE GM-1111. D. MPO activity measurement of LL-37 injection with different treatments.
E. Area of erythema from LL-37 injection. Erythema scores after LL-37 injection were: 5.160.1 after LL-37 alone; 4.960.44 after LL-37+ HA; 2.360.7
after LL-37+ SAGE (P,0.05 LL-37 alone vs LL-37+ SAGE). *P,0.05 vs intradermal LL-37 alone; n=6 per group.
doi:10.1371/journal.pone.0016658.g008
Figure 7. Topical SAGE reduces LL-37-induced inflammation. Balb/c mice were injected intradermally as described in Figure 5, and treated
topically with GM-1111-1 (1% w/w) in a triglyceride-based emollient. A–C. Gross pictures of LL-37 injected skin region: A, no treatment; B, GM-1111
treatment immediately (t=0) after LL-37 injection; C, GM-1111 treatment beginning at t=12 h after LL-37 injection. D. H&E-stained cross-sectional
view of a LL-37 injected skin sample. E. H&E-stained cross-sectional view of GM-1111 treatment at t=0 in LL-37 injected skin region. F. H&E-stained
cross-sectional view of GM-1111 at t=12 h treatment in LL-37 injected skin region. G. MPO activity measurement of LL-37 injection with different
treatments. H. Area of erythema from LL-37 injection. *P,0.05 vs intradermal LL-37 alone; n=6 per group.
doi:10.1371/journal.pone.0016658.g007
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Heparin also neutralizes the toxicity of other cationic peptides,
including eosinophil major basic protein and eosinophil cationic
protein [23,24]. This led us to hypothesize that the SAGEs could
charge neutralize and reduce the biologic effects of exuberantly
expressed LL-37 in humans with rosacea. The data from in vitro
(Figure 4) and in vivo (Figures 5 and 7) experiments support this
hypothesis. GM-1111 not only bound LL-37 (Figure 4A) and
inhibited LL-37 when co-mixed with it prior to intradermal
injection (Figure 5), but also when applied topically to the skin
(Figure 7). Because LL-37 is also overexpressed in psoriatic skin,
where it has been proposed to form complexes with human self-
DNA to activate plasmacytoid dendritic cells and the processes
that lead to lesions of psoriasis [5,25], GM-1111 or other SAGEs
Figure 9. Topical SAGE penetrates into inflamed mouse skin. Balb/c mice were injected intradermally with LL-37 every 12 h for 48 h as in
Figure 7. Control emollient [3% (w/w) methylcellulose] or emollient containing Alexa Fluor 633-labeled GM-1111 was applied topically to the injected
skin after the last two LL-37 injections. Under low light conditions, skin was harvested 12 h after the last emollient application, fixed in
paraformaldehyde and embedded in paraffin. Slides were deparaffinized with xylene, stained with DAPI (1:100 dilution in fluorescent mounting
medium) and imaged using an FV1000 confocal microscope. The skin surface is oriented at the top of each image. A. Skin from controls
demonstrates blue DAPI (lex=358 nm; lem=461 nm) image but no SAGE fluorescence. B. Skin treated with Alexa Fluor 633-labeled GM-1111
demonstrates fluorescence (lex=633 nm; lem=647 nm; false colored green in the image) consistent with SAGE penetration into LL-37-inflamed skin.
doi:10.1371/journal.pone.0016658.g009
Figure 10. Topical SAGE reduces ear edema from croton oil. GM-1111 (1%) was applied topically in the croton oil model. A. Normal control
right ear (top) and croton oil painted left ear (bottom). B. H&E section of control normal ear. C. H&E-stained cross-sectional view of a croton oil
painted ear with vehicle treatment. D. H&E-stained cross-sectional view of croton oil painted ear with SAGE treatment. E. MPO activity measurement
in ears. F. Ear thickness differences between left (croton oil) and right (normal) ears. G. Redness difference between right and left ears. *P,0.05 vs
croton oil with vehicle emollient alone (negative control).
doi:10.1371/journal.pone.0016658.g010
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inflammatory skin diseases.
In addition to blocking cathelicidin peptides, SAGEs are also
potent inhibitors of RAGE with at least four of its disparate ligands
(Table 1 and Figure 3). The pathogenic role of RAGE in skin
diseases has only recently been explored. However, RAGE is
already known to be centrally important in photo-ageing [9], the
S100 calgranulins S100A7 and S100A17 are highly upregulated in
psoriatic skin [26], and HMGB-1 has been recently reported to
mediate cutaneous inflammation from topical croton oil [19]. Our
finding that S100A8, the mouse homologue for human S100A12
[17], is increased in LL-37-injected skin (Figure 6) suggests that
S100 calgranulins also may have a prominent role in the
cutaneous inflammation seen in patients with rosacea.
RAGE is a promiscuous pattern recognition receptor from the
immunoglobulin superfamily and plays a prominent role in
magnifying inflammation [27,28]. Once ligated, RAGE mediates
post-receptor signaling including activation of nuclear factor-kB (NF-
kB), leading to a profound inflammatory response [27,28]. Through
a prominent NF-kB-responsive consensus sequence in its promoter,
RAGE activation also leads to even greater RAGE expression
[27,28]. Furthermore, RAGE interacts with the leukocyte Mac-1
integrin (CD11b/CD18) and p150,95 (CD11c/CD18) to facilitate
leukocyteinflammatorycellrecruitment[13].Attractionofleukocytes
to inflammation is additionally augmented by interaction of the
RAGE ligands S100 calgranulins and HMGB-1 [13,27–29].
Structurally, RAGE is comprised of three immunoglobulin-like
regions: a distal ‘‘V’’ type domain, followed by two ‘‘C’’ type
domains, a short transmembrane domain and a cytoplasmic tail
required for signaling [27,28]. The extracellular domain of RAGE
has been used in detailed analyses of RAGE-ligand interactions [30]
and the crystal structure of the receptor [31]. SAGEs likely inhibit
RAGE-ligand interaction in part through interactions with the V
domain, which consists of a large hydrophobic cavity rimed on its
surface with basic amino acids to form a cationic center [30]. This is
supported by a crystal structure for RAGE which reveals an
elongated molecule with a large basic patch and a large
hydrophobic patch, both highly conserved [31], which might offer
attractive sites for binding of both acidic anionic and alkyl groups,
respectively, of SAGEs. The dramatic differences among structur-
ally similar SAGEs [6] and ligand specific structure-activity
relationships strongly suggest that charge alone is only a small
contributor to overall anti-inflammatory effects. Binding of poly-
anions such as SAGEs to this cationic region might be expected to
not only inhibit binding of AGEs, which ligate RAGE at its V
domain, but also, dependent upon the nature of substituent alkyl
groups, to produce steric interference with the binding of other
ligands such as S100/calgranulins and HMGB-1 which require
adjacent C1 and/or C2 regions for full RAGE ligation [32].
A major issue with the use of sulfated polysaccarides such as
SAGEs for topical treatment of skin diseases is their availability to
the dermis. Literature on the bioavailability of sulfated polysaccha-
rides across skin is conflicting, with some groups reporting little
penetrationbutotherssuggesting transdermal absorption of heparin
and unfractionated heparin as a result of their detergent properties
[33–39]. In the most recently published work, fluorescent-labeled
unfractionated heparin was found to adhere to keratinocytes in
culture, and within48 hours,almosthalf of topicallyappliedlabeled
heparin was found to transcutaneously penetrate the skin of hairless
rats mounted onto a Franz static diffusion cell [40]. Whereas
SAGEs might permeate normal skin in humans less well than in
mice, inflammation could serve to greatly increase SAGE
penetration (Figure 9), as seen with other drugs used for serious
skindiseases[41] and similartothe well-recognized enhancementof
antibiotic penetration into cerebrospinal fluid in the presence of a
disrupted blood-brain barrier in meningitis. Various techniques
have been developed to enable transdermal delivery of low
molecular weight (,5,000 Da) heparin, including penetration
enhancers [42,43], liposomal formulation [43,44], iontophoresis
[45,46] and low frequency ultrasound [45,47,48]. These strategies
might also facilitate dermal penetration of similarly sized SAGEs to
enable their effective topical use in skin disorders.
The chemistry and function of HA have been well explored in
cutaneous biology, and bacterial and animal-derived HA continue
to be an important component for the cosmetics, pharmaceutical
and medical device industries. Our research suggests that simple
chemical modifications of HA can generate novel anionic
polysaccharides with broad anti-inflammatory activities. SAGEs
have the additional advantage of being non-animal derived, thus
circumventing the risks of adulteration and sourcing problems
inherent in animal-derived sulfated polysaccharides [15]. Our
observations suggest that SAGEs in topical application may prove
to be a safe and useful treatment not only for rosacea, but also
other inflammatory skin diseases.
Materials and Methods
Materials
Polyclonal goat anti-human RAGE (Cat# AF1145), recombi-
nant HMGB-1, recombinant human P-selectin/Fc chimera, and
recombinant human RAGE/Fc chimera were purchased from
R&D Systems (Minneapolis, MN). Rabbit polyclonal IgG
antibody to LL-37 (Cat# sc-50423) was from Santa Cruz
Biotechnology (Santa Cruz, CA), and peroxidase-linked goat
anti-rabbit polyclonal IgG (Cat# A0545) was from Sigma Aldrich
(St. Louis, MO). Human S100b calgranulin was from Calbiochem
(San Diego, CA). Alexa FluorH 633 hydrazide was from Molecular
Probes (Eugene, OR). The AGE product CML-BSA was from
MBL International (Woburn, MA). Protein A, horse radish
peroxidase (HRP)-conjugated rabbit polyclonal anti-goat IgG
(Cat# 31402), carbonate-bicarbonate buffer and bovine serum
albumin blocker (10x) were from Piercenet (Rockford, IL). Calcein
AM, Dulbecco’s modified Eagle’s medium (DMEM), EpiLife
medium, ethylenediamine tetraacetic acid (EDTA), fetal bovine
serum (FBS), HEPES, non-essential amino acids, penicillin/
streptomycin/L-glutamine solution, RPMI-1640 without L-gluta-
mine, sodium bicarbonate, and tetramethyl benzidine chromogen
(TMB) single solution chromogen were from Invitrogen (Carlsbad,
CA). High-bind 96-well microplates were from Corning Life
Sciences (Corning, NY), and heparin binding plates were from BD
Biosciences (Bedford, MA). U937 monocytes and nHDF cells were
purchased from American Type Culture Collection (Manassas,
VA). nHEK cells were obtained from Invitrogen (Madison, WI).
Antibodies for immunohistochemistry were sourced as identified in
figure legends. All other chemicals not specified were from Sigma-
Aldrich (St. Louis, MO). HA was obtained commercially from a
recombinant B. subtilis expression system (Novozymes Biopoly-
mers, Bagsvaerd, Denmark) or from streptococcal fermentation
(LifeCore, Chaska, MN).
Animal Care and Use
All animal protocols were approved by the University of Utah
institutional animal care and use committee (IACUC). Approved
protocols include 08-06002, 08-06005 and 08-11008.
Characterization of SAGEs
A variety of SAGEs were prepared with four parameters varied:
molecular weight, type of ether modification, substitution degree
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reported elsewhere [6]. Ether substitution degree (SD) of SAGE
was determined by
1H NMR, and for GM-1111 was estimated to
be SD =1, or ,1 alkyl group per disaccharide unit. After
sulfation, GM-1111 was dissolved in water, dialyzed, and
lyophilized to give a white powder shown by
1H NMR to have
a sulfation SD of 1.0–1.5. Fluorescent-labeled GM-1111 was
synthesized by conjugation with Alexa Fluor 633 hydrazide.
Molecular weight was determined with gel permeation
chromatography using a Waters 515 HPLC pump, Waters 410
differential refractometer, Waters 486 tunable absorbance detec-
tor, and Ultrahydrogel 250 or 1000 columns (7.8 mm i.d X
130 cm) (Milford, MA). Eluent was 200 mM phosphate buffer
(pH 6.5): MeOH =80:20 (v/v), and flow rate was 0.3 or 0.5 mL/
min. The system was calibrated with standard HA samples from
Dr. U. Wik (Pharmacia, Uppsala, Sweden). Average molecular
weight of GM-1111 was ,5,000–6,000 Da.
Formulation of GM-1111 emollient
A 1% (w/w) emollient was prepared in Spectrum Transdermal
Ointment (Lotioncrafters, Olga, WA), a commercially available
proprietary ointment comprised of cetyl ricinoleate, carnuba wax,
D-a-tocopheryl acetate, shea butter, caprylic triglyceride, lecithin
and beeswax. GM-1111 (100 mg) was dissolved in 2.0 g of
nanopure water, ointment was added to give 10.0 g, the mixture
blended thoroughly and the emulsion processed through an
ointment mill. Control emollient was made with 2 g water without
active ingredient. Sodium hyaluronate emollient was prepared
with 100 mg of 53 kDa HA (Novozymes, Bagsvaerd, Denmark)
following an analogous protocol. Each formulation was stored at
4uC.
Cell culture
U937 monocytes were grown in suspension at 37uCi n5 %
CO2-95% air in RPMI-1640 supplemented with 10% heat
inactivated FBS, 2 mM L-glutamine, 1 mM sodium pyruvate,
0.1 mM MEM non-essential amino acids, 100 units/ml
penicillin and 100 mg/ml streptomycin. nHDF cells were
g r o w ni nD M E Ms u p p l e m e n t e dw i t h1 0 %F B Sa n dp e n i c i l l i n -
streptomycin. nHEK cells were grown in EpiLife medium
supplemented with 0.06 mM Ca
2+, 1% EpiLife defined growth
supplement and penicillin-streptomycin. Experiments were
performed with cells from passages 1-5.
Factor XII activation assay
Five ml of pooled normal human plasma was incubated with
100 ml of GM-1111 ranging from 0.1-1000 mg/ml in 0.05M
HEPES containing 0.05% TritonX-100 for 5 min at 25uC.
Amidolytic activity was determined with 0.5 mM H-D-CHT-
Gly-Arg-pNA by following the change of optical density (OD) for
30 min at 405 nm [16]. The OD obtained at 30 min was plotted
against the concentrations of the activator.
Cell surface binding assays
The effect of GM-1111 on binding of U937 monocytes to P-
selectin or RAGE was studied using calcein labeled cells incubated
in micro plates coated with P-selectin-Fc or RAGE-Fc chimeras.
These methods have been reported in detail [10].
Inhibition of human leukocyte elastase (HLE)
Inhibition of HLE by SAGEs was determined using the specific
chromogenic substrate suc-Ala-Ala-Val-pNA, according to meth-
ods previously described [10].
Solid phase binding assays
Three types of ELISAs were performed: one to study the
binding of vascular adhesion molecules and LL-37 to GM-1111,
and another to study binding between RAGE and its ligands,
including CML-BSA, HMGB-1 and S100b. A competitive ELISA
was also performed to study the ability of GM-1111 to inhibit/
compete RAGE binding to its ligands. These ELISAs have been
reported in detail [10].
In vitro cytotoxicity and anticoagulant assays
nHDF cells were seeded (4,000/100 ml medium) in each well of
96-well flat-bottomed microplates, and incubated at 37uCi n5 %
CO2 for 12 hours. Medium was changed with complete medium
containing GM-1111 at final concentrations of 10 to 10
6 ng/ml to
each well. At 48 hours, 20 ml MTS (CellTiter96H Aqueous One
assay; Promega, Madison, WI) was added to each well, and cells
were further incubated for 2 h. Absorbance of the samples was
measured at 490 nm using a 96-well plate reader to determine
cytotoxicity. Cytotoxicity was assessed similarly in nHEK cells.
Automated amidolytic assays for anti-Xa and anti-IIa activity were
performed by BioCascade, Arlington, WI.
Skin irritation tests in mice
SAGEs were tested in vivo to assess dermal irritation potential.
GM-1111 was prepared at 0.1, 1 and 10 mg/ml. Formic acid
(10%) and PBS were used as positive and negative control,
respectively. Balb/c mice (n=6 per group), free from skin
irritation, trauma, or adverse clinical signs prior to study, were
randomized and grouped for test conditions. Backs of animals
were clipped free of fur. Each mouse received four parallel
epidermal abrasions with a sterile needle at the bottom area of the
test site, while the upper area of the test site remained intact.
Under isofluroane anesthesia, two 0.5-ml samples of the test
solution were applied to the entire test site under a double gauze
layer to an area of skin approximately 2.5 cm
2. Patches were
backed with plastic, covered with a non reactive tape and the test
site wrapped with a bandage. After 24 h exposure to the agent, the
bandage and soaked test gauze were removed and test sites were
wiped with tap water to remove remaining test compound. At 24
and 72 h after application, test sites were examined for dermal
reactions in accordance with the FHSA- recommended Draize
scoring criteria [14]. Primary Irritation Index (P.I.I.) of test article
was calculated following test completion. A material producing a
P.I.I. score of greater than or equal to 5.00 would be considered
positive and be classed as a primary irritant to skin.
Peptide synthesis
LL-37 was prepared by the core peptide facility at the
University of Utah, containing the amino acid sequence:
LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES. Syn-
thetic peptides were purified to .95% by HPCL and sequence
was confirmed by mass spectrometry.
LL-37-mediated skin inflammation models
To study the effect of SAGE in rosacea, we used a previously
reported disease model produced by intradermal injection of LL-
37 [3]. Balb/c mice were shaved prior to study to expose skin on
the back. Twenty-four hours later, 40 ml of vehicle (nanopure
water), LL-37 (320 mM), SAGE (1,280 mM), or LL-37+ SAGE mix
(peptide + 4x molar concentration of SAGE) was injected
intradermally into the shaved skin using a 0.5 ml syringe and
31-gauge insulin needle in a manner to raise an intact dermal bleb,
identifying that administration was at the lower epidermis or
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performed by a single investigator with experience performing
intradermal injections on the human volar forearm with needle
bevel facing upward. SAGE and LL-37 were mixed together in
PBS and allowed to incubate 15 min at room temperature before
injection. Injections were repeated every 12 h thereafter. Forty-
eight hours after the initial injection (four injections in total),
animals were anesthetized with isofluorane. Injected skin was
photographed to record severity of erythema and edema. Mice
were euthanized with CO2, and injected skin was excised for
hematoxylin and eosin staining and immunochemistry. From the
center of excised skin, a 6 mm punch biopsy was obtained,
weighed, snap frozen in liquid N2 and stored at -80 C for
measurement of tissue MPO.
To study topical SAGE in this model, mice were injected with
LL-37 as described above. GM-1111 was then applied topically as
a 1% concentration in 50 ml of emollient, either immediately after
the first LL-37 injection or 12 h thereafter, with repeated
application every 12 h after each LL-37 injection. After applica-
tion, emollient was massaged into the affected area of skin with a
gloved finger rubbed 32 consecutive times in a counter-clockwise
direction. Control animals were treated similarly with emollient
alone. To standardize treatment, all topical medication applica-
tions were performed by a single investigator after the individual
performing intradermal injections had finished the injections and
left the laboratory area. After four LL-37 intradermal injections,
mice were photographed and biopsied as above.
Croton oil inflammation model
As another model of PMN-mediated skin inflammation, we
employed croton oil [18]. Croton oil (0.8% solution in acetone)
was painted (10 ml each side) on one ear of Balb/c mice, with the
other ear as a control. Fifteen minutes later, GM-1111 was then
dosed topically as a 1% concentration in 50 ml of emollient applied
to each side of the croton-oil treated ear. After application,
emollient was massaged into each side of the ear with a gloved
finger rubbed 32 consecutive times in a counter-clockwise
direction. Control animals were treated in a similar fashion with
emollient alone. To standardize treatment, all topical medication
applications were performed by a single investigator after the
individual performing croton oil applications had left the
laboratory area. After 4, 8 and 24 h, ear thickness was measured
near the top of the ear distal to the cartilaginous ridges. Change in
ear thickness from control was taken as an edema index. Following
24 h measurements, mice were euthanized with CO2 and 6 mm
ear punch biopsies taken, weighed, frozen and stored at 280uC for
determination of MPO activity. A single investigator performed all
measurements and biopsies in order to standardize the procedure.
Remaining ears were removed, embedded and frozen for
hematoxylin and eosin stains and immunohistochemistry.
MPO assay
Tissue MPO activity was measured using the method of Suzuki
et al. [49] modified by Young et al. [50]. Biopsies were placed in
0.75 ml of 80 mM PBS (pH 5.4) containing 0.5% hexadecyltri-
methyl-ammonium bromide (HTAB). Each sample was homoge-
nized for 45 s at 4uC with a Tissue Tearor Homogenizer (Model
985-370; Biospec Products, Bartlesville, OK). Homogenate was
transferred to a microcentrifuge tube with an additional 0.75 ml
HTAB in PBS. The 1.5 ml sample was centrifuged at 12,0006g for
15 min at 4uC. Triplicate 30 ml samples of the resulting supernatant
were added to 96-well microtiter plates. For MPO assay, 200 mlo fa
mixture containing 100 ml of 80 mM PBS (pH 5.4), 85 ml of 0.22 M
PBS (pH 5.4), and 15 ml of 0.017% hydrogen peroxide were added
to each well. To this, 20 ml of 18.4 mM tetramethylbenzidine HCl
in 8% aqueous dimethylformamide (DMF) was added to start the
reaction. Microtiter plates were incubated at 37uC for 3 min, and
placedonice.Thereactionwasstoppedwiththeadditionof30 mlof
1.46 M sodium acetate. MPO activity was assessed at 630 nm and
expressed as optical density (OD)/biopsy.
Immunohistochemistry
LL-37, PBS and LL-37 and SAGE-injected mouse skin was
stained with antibody to mouse Gr-1 to examine neutrophil
infiltration, and also for S100A8 calgranulin, the major RAGE-
binding calgranulin present in murine PMNs [17]. Slides were
deparaffinized and hydrated through Citrisolv and graded ethanol
washes.Endogenous peroxidase activitywas blocked with 1%H2O2
in PBS with 0.1% Tween-20 (PBST) for 20 min. Antigen retrieval
was performed by microwaving in 1% antigen unmasking solution
(Vector Laboratories) for 20 min followed by incubation at room
temperature for 30 min. Immunostaining was performed using the
Vectastain Elite ABC peroxidase kit (Vector Laboratories). Briefly,
non-specificantibody bindingwas minimized by incubatingsections
for 90 min in diluted normal blocking serum. Sections were
incubated overnight at 4uC in a humidified chamber with primary
goat anti-mouse calgranulin A antibodies (Santa Cruz #sc-8113) at
a 1:200 dilution and rat anti-mouse Gr-1 (R&D Systems #RB6-
8C5)ata1:500dilution.Followingovernightincubation,slideswere
washed in PBST for 9 min, incubated 2 h with biotinylated
secondary antibody diluted to 5 mg/ml in PBST, followed by
Vectastain Elite ABC Reagent (Vector) diluted in PBST for 30 min.
Between incubations, sections were washed for 12 min in PBST.
Immunoreactivity was detected by incubating with the DAB
peroxidase substrate kit (Vector Laboratories) for 1–2 min. Sections
were then washed in nanopure water and counterstained with
hematoxylin before dehydration and mounting with coverslips.
Statistical Analysis
All experiments were performed in triplicate or quadruplicate
for in vitro tests. Results are expressed as means 6 standard error of
the mean (SEM). Significant differences between samples were
calculated by comparison of means using the Aspin2Welch test.
In experiments with multiple groups or treatments, a one-way
analysis of variance (ANOVA) followed by Student-Newman-
Keuls post hoc test was used to analyze for group differences.
Significance was declared at P,0.05.
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